Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

ConditionAcute Lymphoblastic Leukemia

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-60

SponsorPETHEMA Foundation

About this trial

After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.

Eligibility criteria

Qualifiers

Patients 18-60 yr with de novo Ph-neg ALL

Eastern Cooperative Oncology Group (ECOG) 0-2 (or >2 if due to ALL)

Informed consent

Disqualifiers

Mature B-ALL, Ph+ ALL or blast crisis of chronic myeloid leukemia (CML), ALL of ambiguous lineage

ECOG >2 not due to ALL

Impaired cardiac, respiratory, hepatic or renal function not due to ALL

Pregnancy

Trial design

Treatments tested in this trial

Pediatric-type of chemotherapy
allogeneic HSCT

Treatment groups

300 Participants

are divided into 2 treatment groups

Locations108

Select a site below to view it on the map.

Sponsors and collaborators

PETHEMA Foundation

Lead sponsor

Source ClinicalTrials.gov